| Sep-20-2010 |
|
ProNAi Initiates Phase I Cancer Clinical Study of
PNT2258 |
| Mar-20-2008 |
|
ProNAi
Therapeutics, Inc. Cleared to Begin Phase I Clinical Trials for the
First DNA Interference (DNAi®) Therapeutic |
| Aug-23-2007 |
|
ProNAi
Therapeutics Announces First DNAi® Mechanism of Action Studies for
PNT2258 Oncology Drug Candidate |
| Jun-14-2007 |
|
ProNAi Names
Polymun as Preferred Manufacturer of PNT2258 DNAi®-based Cancer
Therapeutic |
| Apr-17-2007 |
|
ProNAi
Announces Preclinical Success for PNT2258 Therapeutic – Curative
Events in Xenograft Mice for Difficult-to-Treat Non-Hodgkin’s
Lymphoma |
| Mar-05-2007 |
|
ProNAi and
Novosom AG Announce Collaboration to Enable Delivery of DNAi®-based
Cancer Therapeutics |
| Jan-08-2007 |
|
ProNAi
Announces DNA Interference (DNAi®) Drug Development Strategy for
2007 |
| Oct-24-2006 |
|
ProNAi Closes
Successful Bridge Funding Round, Secures $6.65 Million Total |
| Oct-12-2006 |
|
ProNAi
Announces New Scientific Advisory Board |
| Sep-26-2006 |
|
ProNAi
Announces Executive Team Buildup, Names New CEO and Top Development
Management |
| Sep-12-2006 |
|
ProNAi Wins
$3.3 Million Funding from Michigan Economic Development Corporation |
| Oct-19-2005 |
|
ProNAi
Therapeutics Raises $4.25m to Develop a New Class of Therapies That
Target DNA |
| |
|
|
